P42 Evaluating the impact of triple combination modulators on medication adherence in cystic fibrosis
Conclusion
These early preliminary results suggest that adherence to TCM is overestimated in SRQs and pharmacy data in comparison to MEMS®. These trends are similar to those shown in previous studies [1-3]. As a result of the high dropout rate a feedback form has been developed to gain a better insight into the reasons why continued participation is low. Recruitment and data collection is ongoing. 6+ arm is due to commence recruiting in Q4 2021.
References
Mehta Z, Kamal KM, Miller R, Covvey JR, Giannetti V. Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national spec...
Source: Archives of Disease in Childhood - April 20, 2022 Category: Pediatrics Authors: Sutton, S., McNally, P., Howlett, M., Hayden, J. Tags: Oral presentations Source Type: research
Medical interventions for chronic rhinosinusitis in cystic fibrosis
CONCLUSIONS: We identified no eligible trials assessing the medical interventions in people with cystic fibrosis and chronic rhinosinusitis. High-quality trials are needed which should assess the efficacy of different treatment options detailed above for managing chronic rhinosinusitis, preventing pulmonary exacerbations and improving quality of life in people with cystic fibrosis.PMID:35390177 | DOI:10.1002/14651858.CD012979.pub3 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - April 7, 2022 Category: General Medicine Authors: Tulasi Kota Karanth Veena Kota Laxminarayan Kl Karanth Bryan K Ward Bradford A Woodworth Laxminarayan Karanth Source Type: research
Intrapleural fibrinolysis and DNase versus video-assisted thoracic surgery (VATS) for the treatment of pleural empyema (FIVERVATS): protocol for a randomised, controlled trial - surgery as first-line treatment
Introduction
Pleural empyema is a frequent disease with a high morbidity and mortality. Current standard treatment includes antibiotics and thoracic ultrasound (TUS)-guided pigtail drainage. Simultaneously with drainage, an intrapleural fibrinolyticum can be given. A potential better alternative is surgery in terms of video-assisted thoracoscopic surgery (VATS) as first-line treatment. The aim of this study is to determine the difference in outcome in patients diagnosed with complex parapneumonic effusion (stage II) and pleural empyema (stage III) who are treated with either VATS surgery or TUS-guided drainage and intraple...
Source: BMJ Open - March 9, 2022 Category: General Medicine Authors: Christensen, T. D., Bendixen, M., Skaarup, S. H., Jensen, J.-U., Petersen, R. H., Christensen, M., Licht, P., Neckelmann, K., Bibby, B. M., Moller, L. B., Bodtger, U., Borg, M. H., Saghir, Z., Langfeldt, S., Harders, S. M. W., Bedawi, E. O., Naidu, B., Ra Tags: Open access, Respiratory medicine Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
CONCLUSIONS AND RELEVANCE: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.PMID:35184602 | DOI:10.1177/10600280221077383 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 21, 2022 Category: Drugs & Pharmacology Authors: Christopher Francis Janowak Bradley Robert Becker Carolyn Dosen Philpott Amy Teres Makley Eric William Mueller Christopher Allen Droege Molly Elizabeth Droege Source Type: research
